MarketPulse
L

$LGND

9 articles found
4 positive
0 negative
5 neutral
The Motley FoolThe Motley Fool··Eric Trie

Villere St Denis Liquidates $18M Euronet Stake Amid Year-Long Underperformance

Villere St Denis completely exits $17.53M Euronet Worldwide position as shares decline 25.4% year-over-year, signaling institutional skepticism.
VCVXLMTAMJBJPM+9stock underperformanceSEC filing
GlobeNewswire Inc.GlobeNewswire Inc.··Schall Law Firm

XOMA Royalty Faces Fiduciary Duty Probe Over $739M Ligand Acquisition

Schall Law Firm investigates XOMA Royalty's $739M Ligand acquisition for potential fiduciary duty breaches; shareholders invited to participate.
LGNDXOMAXOMAOXOMAPshareholder rightsacquisition
BenzingaBenzinga··Vandana Singh

Ligand Pharmaceuticals Acquires XOMA for $739M to Expand Royalty Portfolio

Ligand Pharmaceuticals acquires XOMA Royalty for $739M, immediately accretive to EPS with 2026 guidance raised to $8.50–$9.50 per share.
LGNDXOMAXOMAOXOMAPacquisitionM&A
GlobeNewswire Inc.GlobeNewswire Inc.··Monteverde & Associates Pc

Class Action Firm Probes XOMA-Ligand Deal: Shareholders Question $39 Acquisition Price

Monteverde & Associates investigates XOMA Royalty's $39-per-share sale to Ligand Pharmaceuticals, questioning whether terms are fair to shareholders.
LGNDXOMAXOMAOXOMAPHLX+3acquisitionclass action
BenzingaBenzinga··Na

Ligand to Acquire XOMA Royalty for $739M, Bolstering Biopharma Portfolio to 200+ Assets

Ligand Pharmaceuticals to acquire XOMA Royalty for $39/share in $739M cash deal, expanding portfolio and raising 2026 EPS guidance.
LGNDXOMAXOMAOXOMAPacquisitionbiopharmaceutical
The Motley FoolThe Motley Fool··Jonathan Ponciano

Ligand CFO Cashes In on 80% Rally; Strong Fundamentals Support Gain

Ligand Pharmaceuticals CFO Octavio Espinoza sold $688K in stock under a prearranged plan. The sale reflects portfolio diversification, not concerns, as the biotech firm posts strong 2025 results.
LGNDbiotechearnings growth
BenzingaBenzinga··Vandana Singh

BofA Initiates Buy on Ligand Pharma, Sees $244 Upside in Royalty Model

Bank of America initiates Buy coverage on Ligand Pharmaceuticals with $244 price target, citing differentiated royalty model and strong Q4 results beating earnings expectations.
LGNDportfolio diversificationearnings beat
The Motley FoolThe Motley Fool··Jonathan Ponciano

Ashford Capital Expands Vicor Position as Power Conversion Demand Accelerates

Ashford Capital increased its Vicor position by $10.94M, betting on sustained demand for power conversion tech in AI and data center infrastructure.
VTIVICRGSATLGNDaerospace and defensedata centers
The Motley FoolThe Motley Fool··Jonathan Ponciano

Ashford Capital Trims $11M Cavco Position Amid Portfolio Rebalancing

Ashford Capital sold $11M of Cavco Industries shares, cutting stake from 3.1% to 1.87% in portfolio rebalancing. Cavco shows operational strength despite underperforming broader markets.
VTIGSATLGNDCVCOfund sellingcapital rotation